HLB resolves issues behind FDA setback for novel liver cancer drug

The U.S. Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB’s liver cancer drug Rivoceranib can be addressed through voluntary corrective actions, easing market concerns over the treatment. HLB said Wednesday that its U.S. subsidiary Elevar Therapeutics has received a close-out letter regarding the FDA’s current good manufacturing practice (cGMP) inspection of a facility operated by its Chinese partner Jiangsu Hengrui Pharmaceuticals that produces the drug substance for Rivoceranib. In the letter, the FDA said the facility was generally in compliance with cGMP requirements and classified the inspection findings as Voluntary Action Indicated (VAI). VAI is an inspection classification indicating that the FDA identified issues at a facility but did not consider them serious enough to force regulatory action. HLB said the letter also stated that the VAI classification itself would not affect the FDA’s review of the pending application related with the facility. HLB has received three Complete Response Letters (CRLs) from the FDA regardi

Related Posts

Latest News from Korea

Latest Entertainment from Korea

Learn People & History of Korea